TrialPituitary2015

Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.

Jochen Schopohl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.